van Kasteren M E, Natsch S, van der Meer J W
Academisch Ziekenhuis, afd. Algemene Interne Geneeskunde, Nijmegen.
Ned Tijdschr Geneeskd. 1997 Dec 6;141(49):2392-6.
In the past few years several new antibiotics became available, but no major inventions as to new treatment strategies were made. There are a few new broad-spectrum antibiotics for the intravenous route like piperacillin-tazobactam, the carbapenem meropenem and the fourth-generation cephalosporins. cefepime and cefpirome. New oral antibiotics include the third-generation cephalosporins ceftibuten, cefetamet and cefpodoxime and the macrolides clarithromycin and azithromycin. The last two have the great advantage of less frequent dosing and fewer side effects than erythromycin. Of the two new quinolones, sparfloxacin and trovafloxacin, trovafloxacin is the more promising. In the treatment of Gram-positive infections the glycopeptide teicoplanin became available and the combined derivatives quinupristin-dalfopristin may prove valuable in the future.
在过去几年里,有几种新型抗生素问世,但在新的治疗策略方面没有重大发明。有几种用于静脉途径的新型广谱抗生素,如哌拉西林 - 他唑巴坦、碳青霉烯类美罗培南和第四代头孢菌素头孢吡肟和头孢匹罗。新型口服抗生素包括第三代头孢菌素头孢布烯、头孢他美酯和头孢泊肟酯以及大环内酯类克拉霉素和阿奇霉素。后两者比红霉素具有给药频率更低和副作用更少的巨大优势。在两种新型喹诺酮类药物司帕沙星和曲伐沙星中,曲伐沙星更有前景。在革兰氏阳性菌感染的治疗中,糖肽类替考拉宁已可用,联合衍生物奎奴普丁 - 达福普汀未来可能证明有价值。